Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
about
Growth factor and signaling pathways and their relevance to prostate cancer therapeuticsAndrogen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesEvolving landscape and novel treatments in metastatic castrate-resistant prostate cancerSRC: marker or actor in prostate cancer aggressivenessRecent progress in pharmaceutical therapies for castration-resistant prostate cancerRole of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate CancerNovel non-AR therapeutic targets in castrate resistant prostate cancerCombined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathwaysA randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Recent advances in bone-targeted therapies of metastatic prostate cancerCytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro.Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.Bone-targeting agents in prostate cancer.Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targetsA phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancerCurrent treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasisInhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transitionCastration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.Cancer-targeted therapies and radiopharmaceuticalsOncogene-specific activation of tyrosine kinase networks during prostate cancer progression.Emerging targeted therapies for castration-resistant prostate cancer.Dasatinib suppresses invasion and induces apoptosis in nasopharyngeal carcinoma.Future perspectives of prostate cancer therapy.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Novel therapies for the treatment of advanced prostate cancer.SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.Clinical review: kinase inhibitors: adverse effects related to the endocrine system.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.New and emerging therapies for bone metastases in genitourinary cancers.Ligand-independent activation of MET through IGF-1/IGF-1R signaling.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Src controls castration recurrence of CWR22 prostate cancer xenografts.Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.
P2860
Q26827975-D09A3607-B1AC-4ED4-AF4A-F77A7A89F812Q26866135-9C012CEE-838E-42DC-8835-30D25C7EEA38Q27010542-2BB0A178-D73A-49EF-9D45-4CD6E57C2DCCQ27012541-35CECF97-8D9F-4EFF-990C-E08F79000739Q27022567-2ACF1C1B-E17E-4925-A422-71E172D14012Q28075965-EC30FDC5-3251-4677-994E-3B03728FE1E0Q28383663-991152B3-E15D-43D0-9744-047B9C4AD4F1Q28484572-FEBA4F4A-0FBD-4D78-AB6F-1EDCC0723F3EQ33415009-0A331BE4-562D-4D1D-BE85-65C7704651FEQ33703763-9D806DB2-5373-46E5-A23F-620CD2099CF8Q33744855-0BF9E263-9C40-4989-AB3B-5C933FA128B1Q33778101-05A9FF1C-F6C4-449A-AA2B-0E6F6B149AF5Q33789192-26CFEDF6-4DBC-4765-A571-4BCF8B83ECF0Q33864723-1330AA12-0D2B-46AB-AA70-3C7B0ADE22BBQ34023663-27010008-E065-4FFB-80B9-5923F9349534Q34322294-C4BCFFB4-BCA5-4307-9BFB-EBFA13D30994Q34448130-403CA915-6E3E-424C-A50F-5425F8CDC1B2Q34722000-DDCC3C59-E41D-44F7-B51A-6C73D5196C56Q35119820-CB72F595-8FE3-44FB-91A6-78CE73CBF58DQ35541792-A760C3D7-FDB9-45A6-BD41-63B215DEF1A2Q35683440-8E24A243-13D5-4266-99AA-DB52FA7ECEF5Q35749654-492DB6F8-3F12-4868-A9A6-24F70CCAA984Q35999255-956576E5-A58E-4468-8C54-B88F7B0504C7Q36014173-169EFC8F-9FF9-41E6-8E6F-056760DD88C1Q36076453-F63E0D7F-20D5-4412-92AF-2A7FD7C3C94CQ36140620-F585F018-DE77-4A93-898A-0A4D17EFCA6EQ36665708-2427E181-99B6-4FE7-BD81-EE000CE171E0Q36688923-DB8EE01D-4A6E-44BE-9E97-3C4BE8599C63Q36736494-7FA4115C-8BB8-4A76-A974-DB75A6B3E00AQ36840731-713F09E2-9282-41EC-A5E0-A33001BDA1B3Q36866291-B3D40F09-59CC-4E6D-B484-8B152EF3E63AQ37018397-BC6D4C2E-B34D-4AB0-B5EB-6E53D1B9370AQ37092020-852BFF5D-9375-497A-947C-3B3B6A3F0393Q37166534-C9D753F5-271E-4472-9DDB-3A494748A657Q37185828-C2A43168-15DA-4BD8-B51C-8BF721D89526Q37187646-570B7352-6260-4D6F-9918-D43BDC8235B3Q37481145-C003FDFE-9C36-4986-815A-DAAA29F73904Q37494943-78EC121E-1A51-40E1-81D4-8030715DB5A3Q37594395-5433E1DE-B989-419B-8A93-401AA8C6CAF2Q37720488-1371E87A-8145-4E4E-9405-A170D4137B48
P2860
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dasatinib combined with doceta ...... esults from a phase 1-2 study.
@en
Dasatinib combined with doceta ...... esults from a phase 1-2 study.
@nl
type
label
Dasatinib combined with doceta ...... esults from a phase 1-2 study.
@en
Dasatinib combined with doceta ...... esults from a phase 1-2 study.
@nl
prefLabel
Dasatinib combined with doceta ...... esults from a phase 1-2 study.
@en
Dasatinib combined with doceta ...... esults from a phase 1-2 study.
@nl
P2093
P2860
P356
P1433
P1476
Dasatinib combined with doceta ...... esults from a phase 1-2 study.
@en
P2093
Andrew J Armstrong
Christopher J Logothetis
Edward L Braud
Edwin Posadas
Gary E Gallick
Géralyn C Trudel
John C Araujo
Mathew Lonberg
Paul Mathew
Prashni Paliwal
P2860
P356
10.1002/CNCR.26204
P407
P577
2011-07-25T00:00:00Z